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 47 
-       Abbreviations 48 
-AFT: Antifungal Therapy 49 
-APACHE: Acute Physiology and Chronic Health Evaluation 50 
-ARDS: Acute Respiratory Distress Syndrome 51 
-BAL: Bronchoalveolar Lavage 52 
-CT: Computed Tomography 53 
-EORTC/MSG: European Organisation for the Research and Treatment of Cancer/Mycosis 54 
Study Group 55 
-FOB: Fiberoptic Bronchoscopy 56 
-GM: Galactomannan 57 
-ICU: Intensive Care Unit 58 
-IPA: Invasive Pulmonary Aspergillosis 59 
-SMR: Standardised Mortality Ratio 60 
 62 
-SOFA: Sequential Organ Failure Assessment 61 
 63 
64 
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Highlights: 65 
· Diagnostic and treatment decisions appear to be based both on recognition of risk 66 
factors for IFI and disease severity. 67 
· Mortality of suspected pulmonary aspergillosis in critically ill patients is appallingly high. 68 
· Initiation of AFT does not seem to significantly alter the prognosis. Better diagnostic 69 
tools and strategies are needed. 70 
 71 
Abstract 72 
Background: Invasive pulmonary aspergillosis (IPA) is an increasingly recognized problem in 73 
critically ill patients. Little is known about how intensivists react to a Aspergillus-positive respir-74 
atory sample and about the efficacy of antifungals. Our goal was to identify drivers of antifungal 75 
therapy (AFT) prescription and diagnostic workup in patients with Aspergillus isolation in res-76 
piratory specimens as well as the impact of AFT in these patients. 77 
Methods: ICU patients with a Aspergillus-positive respiratory sample from the database of a 78 
previous observational multicenter study were analysed. Cases were classified as proven/putative 79 
IPA or Aspergillus colonization. Demographics, microbiological, diagnostic and therapeutic data 80 
were collected. Outcome was recorded 12 weeks after Aspergillus isolation.  81 
Results: Patients with putative/proven IPA were more likely to receive AFT than colonized 82 
patients (78.7% vs. 25.5%; p<0.001).  83 
Patients with host factors for invasive fungal disease or multiorgan failure (SOFA score >7)  84 
were more likely to receive AFT (72.5% vs. 37.4%; p<0.001) (68.4% vs. 29.8%; p<0.001).  85 
Once adjusted for disease severity, initiation of AFT did not alter the odds of survival (HR 1.40 86 
95% CI [0.89-2.21]). Likewise, treatment within 48 hours following diagnosis did not change the 87 
clinical outcome (75.7% vs. 61.4%; p=0.63).   88 
Conclusions: Treatment decisions appear to be based on diagnostic criteria and underlying dis-89 
ease severity at the time of Aspergillus isolation. IPA in this population has a dire prognosis and 90 
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AFT is not associated with reduced mortality. This may be explained by  delayed diagnosis and  91 
an often inevitable death due to advanced multiorgan failure.   92 
 93 
Keywords: invasive pulmonary aspergillosis; delayed diagnosis; therapy; critical illness 94 
Introduction  95 
 109 
Aspergillus spp. is a saprophytic filamentous and potentially pathogenic fungus that is wide-96 
spread in the environment (1). The main pathogenic mechanism is inhalation of Aspergillus 97 
spores or conidia. As such, the respiratory tract is affected in the vast majority of cases of inva-98 
sive aspergillosis. Aspergillus is mainly considered a pathogen affecting immunocompromised 99 
hosts and the European Organization for the Research and Treatment of Cancer/Mycosis Study 100 
Group (EORTC/MSG) developed well-defined diagnostic criteria for such patients (2). In recent 101 
years, however, Aspergillus’ importance as a potential pathogen in critically ill patients has been 102 
repeatedly emphasized (3,4). Underlying conditions such as chronic obstructive pulmonary dis-103 
ease or cirrhosis, as well as high severity of acute illness, as evidenced by acute respiratory dis-104 
tress syndrome (ARDS), sepsis and multiorgan failure, add to the risk profile of invasive 105 
aspergillosis in ICU patients (5,6,7). In critically ill patients, the diagnosis of invasive pulmonary 106 
aspergillosis (IPA) is challenging as it often depends on histological samples, which may be 107 
risky to obtain in patients with severe physiological instability.  108 
Aspergillus spp. isolation in respiratory samples occurs in up to 2% of ICU patients (4,5,8) and 110 
its interpretation is equivocal. If the culture represents IPA, antifungal therapy (AFT) should be 111 
initiated promptly as this disease is ultimately fatal in the absence of appropriate therapy. How-112 
ever, if the isolate represents Aspergillus colonization, initiating AFT could be deemed antimi-113 
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crobial misuse with deleterious effects for patient and fungal ecology (9,10,11,12). As such, the 114 
finding of an Aspergillus-positive respiratory tract aspirate creates a dilemma: should AFT be 115 
started or not? An important element is the urgency with which decisions need to be taken. In a 116 
large multicentre cohort of patients with IPA, mortality at 1 week following the initial 117 
Aspergillus-positive culture was about 35% (13). This observation illustrates that there is neither 118 
room for a watchful waiting strategy nor for an extensive diagnostic workup. Moreover, it is 119 
likely that at least some uncertainty about the diagnosis will remain, as diagnosing IPA in unsta-120 
ble critically ill septic patients is particularly problematic (14). In non-critically ill 121 
immunocompromised patients, early initiation of appropriate antifungal therapy has lead to im-122 
proved survival rates (15,16) and there is no reason whatsoever to assume that this would be dif-123 
ferent in ICU patients with IPA. 124 
 125 
 132 
In order to support medical decision-making in case of an Aspergillus-positive respiratory tract 126 
isolate, Vandewoude et al (5) developed a simple algorithm to discriminate colonization from 127 
invasive disease. This algorithm was externally validated in a large multicentre study and led to 128 
the diagnostic category of “putative IPA” (13). There is, however, scant data about the way 129 
intensivists react to the isolation of Aspergillus spp. in a clinical sample and about the impact of 130 
AFT use. 131 
 136 
The present study aims at describing the decision-making process of intensivists in the setting of 133 
Aspergillus spp. recovery from a respiratory tract sample and to ascertain the impact of AFT on 134 
short-term outcome of ICU patients with putative or proven IA. 135 
137 
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 138 
Methods 139 
This is a secondary analysis based on the AspICU database. The cohort consisted of patients ad-140 
mitted to one of the participating ICUs (27 from Europe, 2 from Asia and 1 from Brazil).  141 
Patients were eligible for inclusion in the original study if they had at least one Aspergillus-142 
positive culture on any body site, sampled during the ICU course. Due to the low frequency of 143 
this event, retrospective data from historical cohorts was also accepted provided that all the 144 
required information was available. Clinical suspicion of invasive aspergillosis prior to ICU ad-145 
mission was an exclusion criterion.  146 
 155 
The local ethics committee/institutional review board of each participating center approved the 147 
study. Because of the observational nature of the study and the lack of any modification in the 148 
general management of these patients, the need for informed consent was waived. A complete 149 
and detailed description of the study methodology has been reported elsewhere (13). Basic de-150 
mographic and admission data, acute and underlying conditions and the presence of signs sug-151 
gestive of invasive fungal disease were noted. Data regarding diagnosis and treatment, including 152 
sampling techniques, mycological tests, and test results, as well as radiological tests performed 153 
were also recorded. 154 
For the purpose of this analysis we exclusively considered patients who had Aspergillus recov-156 
ered from the respiratory tract, whatever the number of respiratory specimens with Aspergillus, 157 
as they represented the vast majority of the cohort and allowed for a more homogenous study 158 
population. Patients were categorized as either proven or putative IPA or Aspergillus coloniza-159 
tion, according to validated criteria (2,8,13). According to these criteria suggestive clinical signs 160 
and symptoms are fever despite more than 3 days of antibiotic therapy, new onset fever despite 161 
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antibiotic therapy, pleuritic chest pain, pleural rub, dyspnoea, haemoptysis, and worsening res-162 
piratory failure (8,13). Suggestive features on chest CT-scan include dense, well-circumscribed 163 
lesions with or without a halo-sign, air-crescent sign, or cavitation (2). We sought to analyse di-164 
agnostic-related procedures, namely comparing patients that were deemed to require treatment 165 
(IPA) and those that were considered to be simply colonised. When analysing the use of diagnos-166 
tic tests and impact of AFT, we further excluded patients that did not receive treatment due to 167 
decisions of limitation of care or in whom the diagnostic suspicion of IPA occurred post-mortem. 168 
From a treatment perspective, we analysed the choice of first-line AFT and the outcomes associ-169 
ated with different agents. The need to switch to an alternate agent was also considered as was 170 
the use of combination therapy. Finally, the impact of AFT in the different diagnosis categories 171 
defined by the clinical algorithm (i.e. colonisation or putative/proven IPA) was assessed. 172 
 173 
 181 
For continuous variables, median and interquartile ranges (IQRs) are presented. Group compari-174 
sons were carried out using chi-square and Mann-Whitney U tests, as appropriate. Cox propor-175 
tional hazards regression model was used for survival analysis. Hazards ratio (HR) and 95% con-176 
fidence intervals (95%CI) were calculated in univariate analysis and a multivariate stepwise 177 
model was designed to include baseline variables associated with mortality and other known risk 178 
factors. IBM SPSS Statistics (version 20) was used. P values <0.05 were considered statistically 179 
significant. 180 
182 
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 183 
Results 184 
Description of the cohort 185 
The total cohort of the AspICU study consisted of 563 patients of whom 529 had evidence of 186 
respiratory infection or colonisation. Of these, 20 were not considered as they had another prob-187 
able source of infection and another 5 were excluded as the diagnosis was made post-mortem 188 
and they had no previous Aspergillus isolation. Basic demographic characteristics of the remain-189 
ing 504 patients are presented in Table 1. Overall mortality after 12 weeks was 54.8%.  190 
Patient profile and antifungal therapy 191 
Of the 504 patients analysed, 38 were excluded from further analysis due to limitation of care 192 
decisions.  193 
Of the remaining 466 patients, 246 (52.7%) were put on AFT. Patients with criteria for putative 194 
or proven aspergillosis were more likely to be treated with AF than patients without those criteria 195 
(78.7% vs. 25.5%; p<0.001). Figure 1 shows rates of AFT according to patient’s profiles, in 196 
terms of presence of clinical signs and symptoms, host risk factors, disease severity and addi-197 
tional diagnostic procedures performed.
The majority of patients had at least one sign or symptom present (75.3%). The most common 199 
findings  in putative / proven cases were worsening respiratory failure or dyspnoea and persistent 200 
fever despite > 3 days of antibacterials. Of note, the presence of haemoptysis, despite uncom-201 
mon, was much more frequent in putative or proven cases (1.8% vs 8.4%; p<0.001 when com-202 
pared with colonised cases)
  198 
 204 
. 203 
Almost 90% of patients were mechanically ventilated. The majority of patients had at least one 205 
sign or symptom present (75.3%). The rate of AFT given in patients with symptoms was signifi-206 
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cantly higher compared with patients without suggestive signs and symptoms (p<0.001) (Figure 207 
1). EORTC/MSG host factors were present in 204 patients (43.8%). The rate of AFT initiated in 208 
patients with host factors was higher compared with those without (72.5% vs. 37.4%; p<0.001) 209 
(Figure 1). Regarding severity of disease, Figure 1 presents AFT rates according to SOFA scores 210 
at the time of diagnosis. Patients receiving AFT had similar APACHE II scores when compared 211 
with untreated patients but a significantly higher SOFA score (10 vs. 5; p<0.001) at the time of 212 
Aspergillus isolation. This remains true irrespective of the diagnostic classification of patients 213 
(Table 2). Colonised patients put on AFT were more frequently on mechanical ventilation 214 
(93.9% vs. 75.0%), on renal replacement therapy (35.0% vs. 15.9%) and in shock (70.7% vs. 215 
50.0%) (p<0.001, for all comparisons). 216 
 217 
Additional diagnostic workup and antifungal therapy 218 
 226 
With regard to diagnostic procedures, thoracic CT-scan, fiberoptic bronchoscopy (FOB), lung 219 
biopsy, galactomannan (in serum or BAL), serum β-D-glucan or polymerase chain reaction were 220 
performed in, respectively, 41.6%, 42.9%, 20.2%, 12.9%, 0.6% and 0.6% of the cases. All these 221 
tests were more frequently used in patients that were deemed to require AFT (Table 3). Patients 222 
undergoing any diagnostic test had a significantly higher SOFA at the time of diagnosis (9 vs. 5; 223 
p<0.001). However, information on timing of these procedures is not available, namely if they 224 
were performed before or after the initiation of treatment. 225 
Lung biopsies were performed significantly more often in patients with an overt risk profile for 227 
invasive fungal disease as evidenced by the presence of EORTC/MSG host factors. Biopsies es-228 
tablished the diagnosis of IPA (positive culture and evidence of tissue invasion) in 60 patients 229 
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(63.8% of the patients that underwent a biopsy).  Rates of AFT in patients with proven IPA were 230 
96.7%, compared to 52.9% in patients with negative histopathologic examination (p<0.001). 231 
BAL was carried out in 200 patients (42.9%). In 75.5% of these microscopy or culture were 232 
positive for Aspergillus. Specific findings on CT-scan (nodules with/without halo sign, air cres-233 
cent, and cavity formation) seldom occurred (Table 4). In total, 66 patients (34.0% of the pa-234 
tients that performed CT-scan) demonstrated at least 1 clinical feature on chest CT-scan. The rate 235 
of AFT in these patients was higher compared with patients without suggestive CT-scan findings 236 
(p<0.001). 237 
 238 
Antifungal therapy and survival 239 
 248 
Two hundred and forty-six patients were put on AFT (Table 5), and outcome data exists regard-240 
ing 241. Mortality of treated patients was 68.7% and that of patients deemed not to require AFT 241 
was 36.4% (standardised mortality rate (SMR) =0.84) (p<0,001), very similar to the mortality of 242 
patients deemed to be colonised according to the clinical algorithm by Vandewoude et al (38.6%; 243 
SMR=0.90). Out of 188 patients with putative or proven aspergillosis receiving AFT, 73 (38.8%) 244 
got voriconazole as first line treatment (alone or in combination with other antifungal agents) and 245 
51 (27.1%) got a form of amphotericin B. An echinocandin was used in 28 (15%) cases. Survival 246 
rates were respectively 34.2%, 27.4% and 25% for these classes of AFT. 247 
Factors associated with 12-week mortality were SOFA score, presence of shock and presence of 249 
multiple organ dysfunction syndrome. Mortality according to diagnostic classification and de-250 
cision to start AFT is shown in figure 2. 251 
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 255 
In the overall sample, use of AFT was found to be an independent predictor of mortality (adjust-252 
ed HR  1.760 [1.307-2.370]) but this association was lost when looking only at putative or prov-253 
en cases (adjusted HR  1.400 [0.885-2.213]).  254 
 259 
Considering patients with known survival status, no significant differences in mortality were 256 
noted in association with the different choices of initial AFT, after adjustment for disease severi-257 
ty and organ failure.   258 
 266 
Of the 242 patients colonized, according to the Vandewoude clinical rule, data regarding the de-260 
cision to start AFT and outcomes are available for 227 patients. Of these, 58 were given antifun-261 
gal treatment. The mortality of this subgroup was 51.7% (SMR=1.29) and that of the group left 262 
untreated (n=169) was 32.5% (SMR=0.76 - p=0.018). Using multivariate analysis, to correct for 263 
disease severity, namely for SOFA, shock and mechanical ventilation, the mortality difference 264 
was no longer significant (HR 1.25 [0.77-2.02]).  265 
The timing of initiation of therapy, counted from the day that diagnostic criteria were met, was 267 
available for 182 patients with putative or proven IA. Mortality tended to be higher in the 144 268 
patients that started therapy in the first 48 hours after clinical diagnosis when compared with 269 
those beginning therapy at a later time (75.7% vs. 61.4%; p=0.063). SOFA scores were similar in 270 
both groups (10 vs. 9.5; p=0.439). Combination therapy was used as the initial choice in 8 pa-271 
tients (3.4%), but its use increased as further changes in therapy were deemed necessary. Four 272 
received amphotericin B plus itraconazole, 3 voriconazole plus echinocandin and 1 voriconazole 273 
plus amphotericin B. These 8 patients had a median admission APACHE II score of 23.4 and a 274 
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median SOFA score on the day of Aspergillus isolation of 9 [2-15]. Mortality in this group was 275 
62.5%. Out of 21 patients who had combination therapy at any moment during their ICU stay, 276 
eight received an echinocandin combined with an azole or a polyene and 13 received az-277 
ole/polyene combinations (mainly amphotericin B deoxycolate + itraconazole). 278 
 279 
280 
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 281 
Discussion 282 
 292 
This study gives us a clearer picture of how ICU physicians deal with patients in whom 283 
Aspergillus is isolated from respiratory tract samples. The decision-making process appears to 284 
depend mainly on the presence of aspergillosis diagnostic criteria and on severity of disease ex-285 
pression, namely organ dysfunction. Thus, patients with putative/proven IPA are more likely to 286 
receive AFT and, at the same time, patients put on AFT have significantly higher SOFA scores at 287 
the time of clinical diagnosis. Similarly, patients treated with AFs more often undergo diagnostic 288 
procedures. Using multivariate analysis to correct for disease severity, there is no significant 289 
mortality difference between patients treated and not treated with AF, both for the colonized and 290 
the putative/proven populations.  291 
 302 
Taken together, these aspects may be interpreted as meaning that the decision to start AFT is of-293 
ten based not only on detailed microbiological, radiological and clinical examination, which are 294 
the main components of the Vandewoude criteria (8), but also on the perception of patient’s dis-295 
ease severity. As for bacterial disease, in the setting of an acutely deteriorating patient with sus-296 
pected IPA, therapy might be started empirically while awaiting further test results, while in a 297 
more stable patient one might postpone the decision until a more detailed diagnostic assessment 298 
is completed. One caveat, however, is that a true causal relationship between the ordering of di-299 
agnostic procedures and the start of AFT cannot be determined, as it is impossible to establish a 300 
detailed timeline of events. 301 
In our population, both the occurrence of specific IPA findings and the proportion of patients un-303 
dergoing FOB are rather low and GM measurement was used even less often than FOB. The use 304 
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of diagnostic tests in the setting of suspected IPA is well described for the neutropenic popula-305 
tion, but sensitivity seems to be lower in non-neutropenic patients. The identification of a halo 306 
sign in non-neutropenic patients is rare (17), limiting its utility as a diagnostic tool. Other radio-307 
logical features, like the presence of a “reverse halo”, particularly with a thick outer rim, central 308 
reticulation and concomitant pleural effusion, (18,19), or the combination of pulmonary CT and 309 
arteriography (20) may also be helpful. As for GM, it is particularly useful when measured in 310 
BAL fluid, in the setting of neutropenia and suspected IPA (21), as a persistently positive optical 311 
density index may be a trigger for early “pre-emptive” therapy (22). Its use in non-neutropenic, 312 
critically ill patients is less well established. Meersseman (23) suggested that BAL GM assays 313 
might have adequate sensitivity and specificity for the diagnosis of IPA in the ICU, but one third 314 
of the patients in his series had haematological malignancies. More recently, Acosta et al. report-315 
ed a 21-month prospective study on 51 medical ICU patients with lung infection and at least one 316 
risk factor for invasive fungal disease (24). When compared with serum GM measurements, 317 
BAL GM had a better diagnostic performance, with an area under the ROC curve of 0.98. To-318 
gether, these data suggest that there is room for improving the use of diagnostic tests in ICU pa-319 
tients with suspected IPA. 320 
 321 
Regarding the efficacy of AFT, our main finding is the apparent increase in mortality of the 322 
global population after adjusting for the concomitant presence of organ failure and regardless of 323 
the initial choice of AFT. In spite of this fact, this effect was not seen when the analysis was re-324 
stricted to putative/proven cases. Analogously with IPA patients, Aspergillus-colonised patients 325 
receiving AFT also tended to have a higher mortality. Patients receiving AFT had more severe 326 
organ failure but this does not seem to account for all of the observed difference in outcome. We 327 
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suggest that factors such as delayed diagnosis, antifungal-related adverse events, missed diagno-328 
ses other than IPA and mortality associated with other underlying conditions may contribute to 329 
this observation. As such, one should strive to make as firm a diagnosis as feasible, even if em-330 
pirical treatment has been initiated. 331 
 332 
 344 
The absence of a clear advantage of AFT in patients with IPA stresses the limitations of current 333 
approaches to diagnose IPA in critically ill patients. The present cohort includes exclusively pa-334 
tients with an Aspergillus-positive respiratory tract sample. As such, the time-point at which my-335 
cological culture results are reported may be too late to guarantee a beneficial effect of AFT. An 336 
earlier diagnosis of IPA or the identification of high-risk patients potentially benefiting from a 337 
pre-emptive approach seems the challenge for further clinical research. However, on the other 338 
hand, it should be kept in mind that most antifungals in current clinical practice have potentially 339 
serious side-effects and drug-drug interactions and also that initiating treatment for an infection 340 
that is not present may induce a false sense of security contributing to a delay in the right diagno-341 
sis, as critically ill patients have been shown to be at increased risk for opportunistic infections 342 
other than IA (25). 343 
The most commonly used AFs (either alone or in combination), as first line treatment, were 345 
voriconazole and amphotericin B. The fact that there is no significant difference in mortality as-346 
sociated with the choice of initial AFT is most probably related to the severity of the underlying 347 
disease and to the severe acute physiological derangements at the onset of infection, as shown by 348 
APACHE II and SOFA scores. In this setting, small differences of efficacy would be unlikely to 349 
independently influence the prognosis. The choice of voriconazole as the preferred first-line 350 
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agent for this patient population is not surprising in light of the available data suggesting the su-351 
periority of this drug over amphotericin B for the treatment of IPA (26). In addition, in a cohort 352 
of mechanically ventilated haematology patients with invasive aspergillosis (27), voriconazole 353 
treatment was independently associated with reduced mortality risk (hazard ratio 0.5, 95% CI, 354 
0.3-0.9). Until the publication of the Herbrecht trial (19), amphotericin B was the cornerstone of 355 
treatment of invasive aspergillosis and it is still frequently used. Although there are concerns 356 
about the tolerability of the classical deoxycholate formulation, some evidence exists suggesting 357 
that adequate use of this drug can effectively prevent most of its side effects (28, 29). In this 358 
sample, of the 67 patients that were given a polyene as initial treatment, the majority got the 359 
classical formulation and only 21% (14/67) received any of the lipid formulations, suggesting 360 
that it is still considered an adequate option in many ICUs but also possibly reflecting limitations 361 
to the use or reimbursement of the lipid forms in certain countries. The fact that a significant 362 
proportion of patients received echinocandins as initial treatment may raise some questions as 363 
these agents are only approved for salvage therapy of IPA in patients with hematological malig-364 
nancies (30, 31) and reports exist of breakthrough IPA in patients receiving echinocandins for 365 
empirical treatment of febrile neutropenia (32). Combination AFT has been suggested as a possi-366 
ble alternative for severe IFI and the advent of the candins promoted a renewed interest in this 367 
matter, as candins and voriconazole act at different structures of the fungal cell. Two Spanish 368 
scientific societies suggest combination AFT should be used in severely ill patients (33), despite 369 
stating that the evidence for this recommendation is weak. One recent large randomized study 370 
(34) reports a decreased mortality using a combination of voriconazole and anidulafungin over 371 
voriconazole monotherapy in subgroups of patients with proven or probable invasive 372 
aspergillosis. 373 
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Although, some studies have linked early treatment to better outcomes (15,16,35), in our popula-374 
tion an earlier start of AFT appears to be associated with increased mortality, at an almost signif-375 
icant level, but this may be a mere reflection of a higher underlying disease severity of the pa-376 
tients treated earlier. 377 
Our study has some limitations that should be noted. First, it is a secondary analysis of the 378 
AspICU multicenter study and, due to its prospective design, we cannot be sure that the study 379 
protocol itself did not influence management decisions.  380 
Secondly, the algorithm used has flaws, as shown by the fact that a fair number of untreated pu-381 
tative/proven patients survived.  382 
We cannot establish a detailed timeline of diagnostic procedures and treatment decisions thus 383 
limiting our conclusions.  384 
of untreated putative/proven patients survived. Furthermore, loss of … 391 
Furthermore, loss of some patients due to incomplete data collection further reduced certain sub-385 
group sample sizes. It should also be recognised that dosing in critically ill patients can be par-386 
ticularly problematic (36) and that the dataset used does not allow us to look into this, namely 387 
lacking information on doses used and achieved concentrations.  Finally, due to the rapidly 388 
evolving nature of the field of invasive fungal infections, medical decision processes by 389 
intensivists may have already changed. 390 
 392 
393 
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 394 
Conclusions: 395 
In this large cohort of patients, the dismal prognosis of Aspergillus isolation in respiratory sam-396 
ples from ICU patients, either reflecting colonization or infection, becomes evident. Therapeutic 397 
decisions seem to be driven by both the presence of diagnostic criteria and by underlying disease 398 
severity/organ failure at the time of Aspergillus isolation. 399 
A large proportion of these patients received AFT with no apparent reduction of mortality, 400 
regardless of AF used or timing of initiation of therapy. This is probably caused by a combina-401 
tion of late diagnosis and an often inevitable death due to advanced multiorgan failure. 402 
 410 
 In accordance with recommendations, voriconazole is the first-line agent most commonly used. 403 
The lack of outcome difference with different choices and variable timing of initial treatment 404 
probably reflects the major difficulty of establishing a consistent diagnosis in this population. 405 
The high mortality of patients receiving seemingly unneeded treatment should be regarded as 406 
demonstrative of the need to carefully evaluate these patients, namely increasingly incorporating 407 
recent advances in the radiological and laboratorial diagnosis of IPA in our decision-making pro-408 
cess.  409 
411 
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 529 
-Figure 1 title: Rates of antifungal therapy according to patient’s profiles, in terms of presence 530 
of clinical signs and symptoms, host risk factors, disease severity and additional diagnostic pro-531 
cedures performed.  532 
 Bronchoscopy positive on microscopy (mycelium, branching hyphae) and culture. 536 
-Figure 1 legend: IPA, invasive pulmonary aspergillosis; EORTC, European Organisation for 533 
the Research and Treatment of Cancer-Mycosis Study Group; SOFA, sequential organ failure 534 
assessment score 535 
 537 
-Figure 2 title: Mortality according to diagnostic classification and decision to start antifungal 538 
therapy 539 
 541 
-Figure 2 legend: AFT, antifungal therapy; IPA, invasive pulmonary aspergillosis 540 
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Table 1 - Basic demographic characteristics of the population 542 
 Patients (n=504) 
Male sex - n (%) 306 (60.7%) 
Age, years – median (IQR) 65 [53-74] 
BMI Kg/m2 – median (IQR) 24.1 (20.7-27.3) 
Admission data 
Admission type medical - n (%) 354 (70.4%) 
Admission type elective surgery - n (%) 69 (13.7%) 
Admission type emergency surgery / trauma - n (%) 81 (16.1%) 
APACHE II score – median (IQR) 23.0 (17.0-28.0) 
Organ dysfunction at diagnosis 
Vasopressor or inotropic use - n (%) 380 (75.4%) 
Mechanical ventilation - n (%) 453 (89.9%) 
Renal replacement therapy - n (%) 157 (31.2%) 
Median SOFA score at diagnosis (IQR) 7 [4-12] 
SOFA, Sequential Organ Failure Assessment 543 
IQR, interquartile range 544 
 545 
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Table 2: SOFA and APACHE II according to diagnosis and treatment decisions 547 
 Aspergillus  
colonization 
Invasive Pulmonary  
Aspergillosis 
 AFT No AFT P AFT No AFT P 
SOFA score 6 (4-12) 4 (2-8) 0.001 10 (6-12) 7 (4-10) 0.004 
APACHE II 
score 
23 (16-26) 22 (16-28) 0.583 25 (17-29) 22 (15-28) 0.456 
AFT, antifungal therapy 548 
SOFA, sequential organ failure assessment at the time of Aspergillus isolation 549 
APACHE, acute physiology and chronic health evaluation   550 
 551 
 552 
 553 
Table 3: Use of diagnostic tests according to treatment decision 554 
 Total population (n=466) Received AFT (n=246) No AFT (n= 220) p 
CT scan 194 (41.6%) 144 (58.5%) 50 (23.7%) < 0.001 
FOB 200 (42.9%) 158 (64.2%) 42 (19.1%) < 0.001 
Biopsy 94 (20.2%) 76 (30.9%) 18 (8.2%) < 0.001 
GM 60 (12.9%) 58 (23.6%) 2 (0.9 %) 0.002 
BDG 3 (0.6%) 3 (1.2%) 0 ns 
PCR 3 (0.6%) 3 (1.2%) 0 ns 
CT scan, computorized tomography scan 555 
FOB, fiberoptic bronchoscopy 556 
GM, galactomannam 557 
BDG, beta-d-glucan 558 
PCR, polymerase chain reaction 559 
 560 
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Table 4: Specific findings on chest CT scans 562 
 Total Colonization Putative/Proven IPA 
Nodule 56 (11.1%) 10 (4.1%) 46 (17.6%) 
Air crescent sign 4 (0.8%) 0 (0.0%) 4 (1.5%) 
Halo sign 13 (2.6%) 3 (1.2%) 10 (3.8%) 
Cavity 17 (3.4%) 6 (2.5%) 11 (4.2%) 
CT scans, computorized tomography scans 563 
IPA, invasive pulmonary aspergillosis 564 
 565 
 566 
 567 
Table 5: Summary of AFs used as first-line treatment# 568 
Antifungal Treated patients 
n (%) 
Treated Colonized 
patients 
n (%) 
Treated Putative/Proven 
patients 
n (%) 
Amphotericin B deoxycholate 53 (22.0) 15 (28.3) 38 (20.2) 
Amphotericin B lipid-associated 14 (5.8) 4 (7.5) 10 (5.3) 
Echinocandin 34 (14.1) 6 (11.3) 28 (15.0) 
Voriconazole 94 (39.0) 21 (39.7) 73 (38.8) 
Other 46 (19.1) 7 (13.2) 39 (20.7) 
Total 241 (100) 53 (100) 188 (100.0) 
# Data is available, regarding AF used, in 241 out of the 246 patients treated with AFT 569 
 570 
 571 
 572 
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Figure 1. 574 
 575 
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Figure 2. 578 
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